Last reviewed · How we verify
Olanzapine & Quetiapine
Olanzapine and quetiapine are atypical antipsychotics that block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms and stabilize mood.
Olanzapine and quetiapine are atypical antipsychotics that block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder (acute mania and maintenance), Major depressive disorder (adjunctive treatment).
At a glance
| Generic name | Olanzapine & Quetiapine |
|---|---|
| Sponsor | Hamilton Health Sciences Corporation |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Both drugs antagonize dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis, while also blocking serotonin 5-HT2A receptors which may enhance antidepressant effects and reduce extrapyramidal side effects. Quetiapine additionally has alpha-adrenergic and histamine H1 antagonism contributing to sedation and anxiolytic properties. This combination is used to manage symptoms across schizophrenia, bipolar disorder, and treatment-resistant depression.
Approved indications
- Schizophrenia
- Bipolar disorder (acute mania and maintenance)
- Treatment-resistant depression (adjunctive use)
- Psychotic disorders
Common side effects
- Weight gain
- Sedation
- Metabolic syndrome
- Extrapyramidal symptoms
- Orthostatic hypotension
- Hyperglycemia
- Hyperprolactinemia
Key clinical trials
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Enhancing Recovery in Early Schizophrenia (PHASE2)
- National Pregnancy Registry for Psychiatric Medications
- Maternal And Infant Antipsychotic Study
- Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach (PHASE2)
- A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
- Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and (NA)
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olanzapine & Quetiapine CI brief — competitive landscape report
- Olanzapine & Quetiapine updates RSS · CI watch RSS
- Hamilton Health Sciences Corporation portfolio CI